CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...
Industry: Biotechnology
Sector: Healthcare
Phone: 86 10 6508 6063
Address:
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China
